Company intelligence / Profile preview
Kunming Pharmaceutical Group
Kunming, Yunnan, Chinaen.kpc.com.cn ↗
- Ownership
- Private
- Employees
- ~3000
- Development stage
- Other
01
Overview
Kunming Pharmaceutical Group has multiple advanced clinical drug candidates, including a natural medicine for ischemic stroke in phase II, a Class 1 innovative drug for NASH approved for clinical trials, and a dihydroartemisinin program for lupus erythematosus in phase II. The group is China's largest antimalarial manufacturer, with extensive GMP, FDA, and WHO certifications, and a deep commercial pipeline in cardiovascular, chronic, and aging-related diseases[1][2][4][6].
- Therapeutic areas
- ImmunologyInfectious DiseasesGastroenterologyCardiovascularOtherOncology
- Modalities
- Small moleculeBiologicPeptidesFusion proteinTraditional Chinese medicine
- Industry
- Pharma
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Kunming Pharmaceutical Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kunming Pharmaceutical Group.